Patients

WU-CART-007 is an investigational, off the shelf, fratricide-resistant allogeneic CD7 targeted CAR-T  cell  therapy cell under evaluation in a pivotal Phase 2 study for relapsed or refractory (R/R) T cell acute lymphoblastic leukemia/ Lymphoma (T-ALL/LBL). This global study is enrolling pediatric and adult patients.

For more information, visit www.clinicaltrials.gov, study identifier number NCT06514794.